Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2020 | 1 |
2021 | 1 |
2022 | 1 |
2024 | 2 |
Search Results
4 results
Results by year
Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
The following term was not found in PubMed: 36941224
Page 1
Showing results for
Sun M/and/author_id=36941224
Your search for
Sun M/and/cauthor_id=36941224
retrieved no results
Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer.
Nat Med. 2022 Nov;28(11):2353-2363. doi: 10.1038/s41591-022-02047-z. Epub 2022 Nov 10.
Nat Med. 2022.
PMID: 36357680
Free PMC article.
Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021.
GBD 2021 Causes of Death Collaborators.
GBD 2021 Causes of Death Collaborators.
Lancet. 2024 May 18;403(10440):2100-2132. doi: 10.1016/S0140-6736(24)00367-2. Epub 2024 Apr 3.
Lancet. 2024.
PMID: 38582094
Free article.
Item in Clipboard
Global age-sex-specific mortality, life expectancy, and population estimates in 204 countries and territories and 811 subnational locations, 1950-2021, and the impact of the COVID-19 pandemic: a comprehensive demographic analysis for the Global Burden of Disease Study 2021.
GBD 2021 Demographics Collaborators.
GBD 2021 Demographics Collaborators.
Lancet. 2024 May 18;403(10440):1989-2056. doi: 10.1016/S0140-6736(24)00476-8. Epub 2024 Mar 11.
Lancet. 2024.
PMID: 38484753
Free article.
Item in Clipboard
Efficacy of utidelone plus capecitabine versus capecitabine for heavily pretreated, anthracycline- and taxane-refractory metastatic breast cancer: final analysis of overall survival in a phase III randomised controlled trial.
Xu B, Sun T, Zhang Q, Zhang P, Yuan Z, Jiang Z, Wang X, Cui S, Teng Y, Hu XC, Yang J, Pan H, Tong Z, Li H, Yao Q, Wang Y, Yin Y, Sun P, Zheng H, Cheng J, Lu J, Zhang B, Geng C, Liu J, Shen K, Yu S, Li H, Tang L, Qiu R; study group of BG01-1323L.
Xu B, et al.
Ann Oncol. 2021 Feb;32(2):218-228. doi: 10.1016/j.annonc.2020.10.600. Epub 2020 Nov 11.
Ann Oncol. 2021.
PMID: 33188874
Free article.
Clinical Trial.
PATIENTS AND METHODS: In total, 405 patients were randomised 2:1 to receive utidelone (30 mg/m(2) IV daily, days 1-5, over 90 min) plus capecitabine (1000 mg/m(2) orally b.i.d., days 1-14) or capecitabine alone (1250 mg/m(2) orally b.i.d., days 1-14) every 21 …
PATIENTS AND METHODS: In total, 405 patients were randomised 2:1 to receive utidelone (30 mg/m(2) IV daily, days 1-5, over 90 min) pl …
Item in Clipboard
Cite
Cite